NCT06344780进行中（未招募）不适用
A Multi-center Study of the Clinical Outcomes of Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer in Real World Practice
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
A multi-center, real world study to evaluate the clinical outcomes and safety of Abemaciclib, Palbociclib or Dalpiciclib combined with endocrine therapy as first-line treatment in HR Positive, HER2 Negative unresectable or metastatic Breast Cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •age >= 18 years old;
- •Patients who were diagnosed as HR Positive, HER2 Negative recurrent unresectable (local or regional) or stage IV (M1) breast cancer between June 2020 to October 2023;
- •Received CDK4/6 inhibitors(Abemaciclib, Palbociclib or Dalpiciclib) as first-line therapy for at least one cycle;
- •Complete medical history was available.
排除标准
- •Medical history was incomplete.
结局指标
主要结局
PFS
时间窗: 6 weeks
Pregression-free survival
次要结局
- OS(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine TherapyBreastNeoplasm MalignantFemaleNCT04524728Istituti Clinici Scientifici Maugeri SpA191
招募中
1 期
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast CancerMetastasisBreast CancerNCT05095207Icahn School of Medicine at Mount Sinai42
已完成
不适用
The Real-World Data of Treatment with Abemaciclib for HR-positive HER2-negative Metastatic Breast Cancer: A Multicentral Cohort StudyHR-positive HER2-negative Metastatic Breast CancerJPRN-UMIN000043149Aichi Cancer Center200
终止
2 期
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate CancerProstate CancerNCT04298983University of Alabama at Birmingham9
招募中
不适用
Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon.locally advanced or metastatic breast cancerT51.2Breast CancerLBCTR2022035014Eli Lilly100